Clinical Trials
4
Active:0
Completed:0
Trial Phases
2 Phases
Phase 4:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 4
1 (50.0%)DeBakey Cardiovascular Magnetic Resonance Study
Recruiting
- Conditions
- Cardiovascular Diseases
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Dipan Shah
- Target Recruit Count
- 100000
- Registration Number
- NCT04281823
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance
Not Applicable
- Conditions
- Coronary Artery DiseaseCardiomyopathy
- Interventions
- Drug: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)Drug: Cardiac MRI with contrast agent, Gadovist
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Dipan Shah
- Target Recruit Count
- 120
- Registration Number
- NCT03057561
Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study
- Conditions
- Mitral Regurgitation
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Dipan Shah
- Target Recruit Count
- 60
- Registration Number
- NCT02924363
- Locations
- 🇺🇸
Piedmont Heart Institute, Atlanta, Georgia, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- Dipan Shah
- Target Recruit Count
- 50
- Registration Number
- NCT01446094
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
News
No news found